Futura Medical (FUM) Q4 2025 TU earnings summary

Executive summary

• FY25 revenue expected at £1.7 million, surpassing previous guidance of £1.3–£1.4 million.

• Net cash at year-end was £3.4 million, bolstered by a £2.75 million fundraise in November 2025.

• Strategic review of business and operations underway, with results to be published mid-April 2026.

Financial highlights

• Revenue for FY25 projected at £1.7 million, ahead of management expectations.

• Net cash position at year-end was £3.4 million.

• Expected tax credit refund for FY25 is approximately £0.3 million.

Outlook and guidance

• Cash runway expected to last until December 2026, supported by recent fundraising, tax credit, milestone payment, and ongoing sales.

• Anticipated US$2.5 million milestone payment from Haleon in H1 2026, contingent on US patent grant.

• Strategic review outcomes to be disclosed with full year results in April 2026.